Fouad J. Moawad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fouad J. Moawad has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
C. L. Maydonovitch
Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA
3 shared publicationsA. M. Schoepfer
Department of Gastroenterology; University of Lausanne; Lausanne Switzerland
2 shared publicationsCorinne L Maydonovitch
Gastroenterology Service, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA
2 shared publicationsCorinne L. Maydonovitch
Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, Maryland
2 shared publications- Ekaterina Safroneeva
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
2 shared publications Mirna Chehade
Departments of Pediatrics and Medicine, Mount Sinai Center for Eosinophilic Disorders, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York
2 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-246-246
Sa1118 - Eosinophilic Esophagitis-Like Disease with Lack of Significant Esophageal Eosinophilia: Description of a New Disease Entity
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-246-246
Sa1118 - Eosinophilic Esophagitis-Like Disease with Lack of Significant Esophageal Eosinophilia: Description of a New Disease Entity
- 6 July 2016
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1380 (1) , 178-182
Sloughing esophagitis: a spectacular histologic and endoscopic disease without a uniform clinical correlation
Sloughing esophagitis, also currently known as esophagitis dissecans superficialis, is a degenerative disease of the squamous epithelium characterized by superficial epithelial necrosis with parakeratosis, but without inflammation, and detachment of the superficial necrotic zone from the deep viable zone. This leads to a spectacular endoscopic appearance of sloughed mucosa in streaks and patches. The cause is unknown, and the clinical characteristics are variable, ranging from incidentally findings to esophageal symptoms. The disease seems to be self‐limited, as resolution of the changes was observed in the few cases for which follow‐up endoscopic examinations have been reported.
- 6 July 2016
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1380 (1) , 178-182
Sloughing esophagitis: a spectacular histologic and endoscopic disease without a uniform clinical correlation
Sloughing esophagitis, also currently known as esophagitis dissecans superficialis, is a degenerative disease of the squamous epithelium characterized by superficial epithelial necrosis with parakeratosis, but without inflammation, and detachment of the superficial necrotic zone from the deep viable zone. This leads to a spectacular endoscopic appearance of sloughed mucosa in streaks and patches. The cause is unknown, and the clinical characteristics are variable, ranging from incidentally findings to esophageal symptoms. The disease seems to be self‐limited, as resolution of the changes was observed in the few cases for which follow‐up endoscopic examinations have been reported.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S667
Mo1195 Longitudinal Evaluation of Non-Invasive Biomarkers for Eosinophilic Esophagitis
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S667
Mo1195 Longitudinal Evaluation of Non-Invasive Biomarkers for Eosinophilic Esophagitis
- 1 January 2016
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 14 (1) , 23-30
Effects of Race and Sex on Features of Eosinophilic Esophagitis
- 1 January 2016
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 14 (1) , 23-30
Effects of Race and Sex on Features of Eosinophilic Esophagitis
- Open Access
- 1 December 2015
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 6 (12) , e132
Early Comparison of Inflammatory vs. Fibrostenotic Phenotype in Eosinophilic Esophagitis in a Multicenter Longitudinal Study
Tenotic phenotypes. METHODS: Data were obtained from EoE patients from three medical centers and followed prospectively. Endoscopic features and histology from index and follow-up endoscopies were recorded. Behavior was classified as inflammatory if endoscopic findings demonstrated furrows or white plaques and as fibrostenotic if endoscopic findings included fixed rings or strictures. RESULTS: Two hundred and fifty-six EoE patients were included in the analysis. The mean age was 32±18 years, 25% of patients were <18 years, 89% of patients were Caucasians, and 74% of patients were male. The mean duration of symptoms before diagnosis was 6.8±7.2 years with a follow-up of 1.7±1.9 years (maximum follow-up of 12 years). Fifty-four percent of patients presented with fibrostenotic EoE, whereas 46% presented with inflammatory EoE. Patients with inflammatory disease were younger than those with fibrostenotic disease (24±19 vs. 39±15 years,P<0.001). Patients with fibrostenotic disease had a longer duration of symptoms than those with inflammatory disease (8.1±7.7 vs. 5.3±6.3 years,P=0.002). Over the study period, 47 (18%) had remission of inflammatory EoE, 68 (27%) continued to have inflammatory disease, 74 (29%) continued to have fibrostenotic disease, 65 (25%) fibrostenotic patients had regression of fibrosis, and 2 patients (1%) progressed from inflammatory disease to fibrostenotic disease. Patients who had regression from their fibrostenosis were more likely than patients who continued to demonstrate fibrostenosis to have a decrease in proximal (54% vs. 32%,P<0.001) and distal (70% vs. 38%,P<0.001) eosinophilia. CONCLUSIONS: Most EoE patients maintained their phenotype or had an improvement with <1% progressing from inflammatory to fibrostenosis. This suggests that early therapeutic strategies aimed at controlling inflammation may interrupt, decrease, or prevent the remodeling fibrosis in EoE....
- 1 December 2015
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 6 (12) , e132
Open AccessEarly Comparison of Inflammatory vs. Fibrostenotic Phenotype in Eosinophilic Esophagitis in a Multicenter Longitudinal Study
Tenotic phenotypes. METHODS: Data were obtained from EoE patients from three medical centers and followed prospectively. Endoscopic features and histology from index and follow-up endoscopies were recorded. Behavior was classified as inflammatory if endoscopic findings demonstrated furrows or white plaques and as fibrostenotic if endoscopic findings included fixed rings or strictures. RESULTS: Two hundred and fifty-six EoE patients were included in the analysis. The mean age was 32±18 years, 25% of patients were <18 years, 89% of patients were Caucasians, and 74% of patients were male. The mean duration of symptoms before diagnosis was 6.8±7.2 years with a follow-up of 1.7±1.9 years (maximum follow-up of 12 years). Fifty-four percent of patients presented with fibrostenotic EoE, whereas 46% presented with inflammatory EoE. Patients with inflammatory disease were younger than those with fibrostenotic disease (24±19 vs. 39±15 years,P<0.001). Patients with fibrostenotic disease had a longer duration of symptoms than those with inflammatory disease (8.1±7.7 vs. 5.3±6.3 years,P=0.002). Over the study period, 47 (18%) had remission of inflammatory EoE, 68 (27%) continued to have inflammatory disease, 74 (29%) continued to have fibrostenotic disease, 65 (25%) fibrostenotic patients had regression of fibrosis, and 2 patients (1%) progressed from inflammatory disease to fibrostenotic disease. Patients who had regression from their fibrostenosis were more likely than patients who continued to demonstrate fibrostenosis to have a decrease in proximal (54% vs. 32%,P<0.001) and distal (70% vs. 38%,P<0.001) eosinophilia. CONCLUSIONS: Most EoE patients maintained their phenotype or had an improvement with <1% progressing from inflammatory to fibrostenosis. This suggests that early therapeutic strategies aimed at controlling inflammation may interrupt, decrease, or prevent the remodeling fibrosis in EoE....
- 14 July 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (4) , 487-8
Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes? - Author's reply.
- 14 July 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (4) , 487-8
Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes? - Author's reply.
- Open Access
- 24 May 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (2) , 231-238
Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease
Background Proton pump inhibitor‐responsive oesophageal eosinophilia (PPI‐REE) is a recently described entity which resembles oeosinophilic oesophagitis (EoE), yet responds to acid suppressive treatment. Aim To determine whether EoE shares similar staining features with PPI‐REE or with gastro‐oesophageal reflux disease (GERD). Methods This retrospective study consisted of patients with an established diagnosis of EoE, PPI‐REE, or GERD identified from a database during a 1‐year period. Immunohistochemistry (IHC) analysis was performed specifically targeting eotaxin‐3 antibodies. All sections were qualitatively (intensity) and quantitatively (percentage of cells stained) assessed independently by two blinded pathologists. Results The cohort consisted of three groups of patients: EoE (n = 22), PPI‐REE (n = 23) and GERD (n = 23) for a total of 68 patients. Study demographics included mean age 39 (14) years, 75% male and 77% Caucasian. There was a significant difference in the eotaxin‐3 staining among EoE, PPI‐REE and GERD groups [mean score (s.d.): 1.2 (1.2), 0.8 (1.0), 0.3 (0.7), P = 0.006]. Staining scores of EoE patients were significantly higher compared with GERD (P = 0.002) and a trend towards significance was seen between EoE and PPI‐REE (P = 0.054). There was also a significant difference in EoE staining intensity score among the three groups (P = 0.006). Intensity scores of EoE were significantly higher compared with GERD [1.0 (0.9) vs. 0.22 (0.52), P < 0.001]. There was no significant difference between EoE and PPI‐REE groups [1.0 (0.0) vs. 0.52 (0.75) P = 0.094]. Conclusions A difference in eotaxin‐3 staining was seen in the three groups of patients with oesophageal eosinophilia. Eotaxin‐3 can distinguish EoE from GERD, but not from proton pump inhibitor responsive‐oesophageal eosinophilia.
- 24 May 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (2) , 231-238
Open AccessComparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease
Background Proton pump inhibitor‐responsive oesophageal eosinophilia (PPI‐REE) is a recently described entity which resembles oeosinophilic oesophagitis (EoE), yet responds to acid suppressive treatment. Aim To determine whether EoE shares similar staining features with PPI‐REE or with gastro‐oesophageal reflux disease (GERD). Methods This retrospective study consisted of patients with an established diagnosis of EoE, PPI‐REE, or GERD identified from a database during a 1‐year period. Immunohistochemistry (IHC) analysis was performed specifically targeting eotaxin‐3 antibodies. All sections were qualitatively (intensity) and quantitatively (percentage of cells stained) assessed independently by two blinded pathologists. Results The cohort consisted of three groups of patients: EoE (n = 22), PPI‐REE (n = 23) and GERD (n = 23) for a total of 68 patients. Study demographics included mean age 39 (14) years, 75% male and 77% Caucasian. There was a significant difference in the eotaxin‐3 staining among EoE, PPI‐REE and GERD groups [mean score (s.d.): 1.2 (1.2), 0.8 (1.0), 0.3 (0.7), P = 0.006]. Staining scores of EoE patients were significantly higher compared with GERD (P = 0.002) and a trend towards significance was seen between EoE and PPI‐REE (P = 0.054). There was also a significant difference in EoE staining intensity score among the three groups (P = 0.006). Intensity scores of EoE were significantly higher compared with GERD [1.0 (0.9) vs. 0.22 (0.52), P < 0.001]. There was no significant difference between EoE and PPI‐REE groups [1.0 (0.0) vs. 0.52 (0.75) P = 0.094]. Conclusions A difference in eotaxin‐3 staining was seen in the three groups of patients with oesophageal eosinophilia. Eotaxin‐3 can distinguish EoE from GERD, but not from proton pump inhibitor responsive‐oesophageal eosinophilia.
- 16 April 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (10) , 1249-50
Letter: distinguishing PPI-responsive oesophageal eosinophilia from eosinophilic esophagitis - still a long way to go; authors' reply.
- 16 April 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (10) , 1249-50
Letter: distinguishing PPI-responsive oesophageal eosinophilia from eosinophilic esophagitis - still a long way to go; authors' reply.
- 17 March 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (8) , 897-8
Commentary: the proton pump inhibitor test - does it have a role in eosinophilic oesophagitis? Authors' reply.
- 17 March 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (8) , 897-8
Commentary: the proton pump inhibitor test - does it have a role in eosinophilic oesophagitis? Authors' reply.